Teleflex to create a new, independent publicly traded company consisting of its Urology, Acute Care, and OEM businesses.

Piper Sandler analyst Matt O’Brien downgraded Teleflex (TFX) to Neutral from Overweight with a price target of $140, down from $255. The ...

Raymond James downgraded Teleflex (TFX) to Market Perform from Outperform without a price target The firm likes the company’s active portfolio ...

Principal Financial Group Inc. reduced its stake in Teleflex Incorporated (NYSE:TFX – Free Report) by 13.1% during the fourth ...

The Q4 2024 earnings season tapers off from here, with S&P 500® EPS growth surpassing 17%, the highest in 3 years.

After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while ...

Teleflex vascular access (24% of sales) is a no-moat business, in our view. While Teleflex leads the market for central venous catheters, or CVC, tubes that are connected to veins and used to deliver ...

Major indices closed lower on Thursday following earnings from AI-darling Nvidia overnight and an update from Donald Trump ...

Thursday closed down -1.59%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.45% and the Nasdaq 100 Index ($IUXX ...

Teleflex Inc. closed 44.33% below its 52-week high of $249.91, which the company reached on September 27th.

Shares of medical technology company Teleflex (NYSE:TFX) fell 22.9% in the morning session after the company reported ...

Good morning, ladies and gentlemen, and welcome to the Teleflex Fourth Quarter 2024 Earnings Conference Call. At this time all participants have been placed in a listen-only mode. At the end of the ...